dehydroepiandrosterone has been researched along with ritonavir in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Doherty, D; Dvorkin, SA; Rodriguez, EP; Thompson, PD | 1 |
| Blanche, S; Frange, P; Kariyawasam, D; Laborde, K; Parat, S; Polak, M; Simon, A; Souchon, PF | 1 |
3 other study(ies) available for dehydroepiandrosterone and ritonavir
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Vitamin D receptor agonist EB1089 is a potent regulator of prostatic "intracrine" metabolism.
Topics: Androgens; Calcitriol; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dehydroepiandrosterone; Gene Expression Regulation, Neoplastic; Humans; Male; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Calcitriol; Ritonavir; RNA, Messenger; Testosterone | 2014 |
Adrenal enzyme impairment in neonates and adolescents treated with ritonavir and protease inhibitors for HIV exposure or infection.
Topics: 17-alpha-Hydroxypregnenolone; 17-alpha-Hydroxyprogesterone; Adolescent; Adrenal Glands; Anti-HIV Agents; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; HIV Infections; Humans; Hydrocortisone; Infant, Newborn; Male; Protease Inhibitors; Ritonavir; Young Adult | 2014 |